← Back to headlines
BioNTech Anticipates €1.6B-€1.9B Revenue by 2026, Advances Oncology Catalysts
BioNTech projects revenues between €1.6 billion and €1.9 billion by 2026, as the company continues to advance its oncology catalysts into late-stage development by the same year.
4 Aug, 22:01 — 4 Aug, 22:01
Sources
Showing 1 of 1 sources